S1 Biopharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.s1biopharma.com
One-Year Study of S1B-509 vs Placebo for Weight Loss
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- S1 Biopharma, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06517797
Study of S1B-408 in Women With Orgasmic Dysfunction
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- S1 Biopharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06516055
Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety
Phase 1
Completed
- Conditions
- Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined)Sexual Interest/Arousal Disorder (DSM-5 Defined)
- Interventions
- Drug: bupropion, Lorexys low-dose, Lorexys moderate-dose
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- S1 Biopharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01857596
- Locations
- 🇺🇸
Robert Taylor Segraves, MD, PhD, Beachwood, Ohio, United States
🇺🇸Molly Katz, MD, Cincinnati, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath